Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial

Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial of RP103 (delayed-release cysteamine) for the potential treatment of Huntington's disease (HD) in collaboration with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers). A